Categories: Web and IT News

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors


Burlington, Massachusetts–(Newsfile Corp. – November 18, 2025) – Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. The new funds bring the total raised to $112 million and support an ongoing Phase 1 study in Rheumatoid Arthritis (RA) designed to evaluate LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. It also provides for Chemistry Manufacturing and Controls (CMC) preparations to ensure that Phase 2 clinical supply is available without incurring an unnecessary delay. As part of the investment, Christopher Gagliardi, Ph.D., Principal at Sanofi Ventures, will join as an observer on Lifordi’s Board of Directors.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • New strategic investment from Sanofi Ventures, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture
  • Funds support an ongoing Phase 1 study to evaluate LFD-200, and provides for CMC preparations to ensure Phase 2 clinical supply
  • Phase 1 study of LFD-200 in RA is progressing as planned, with initial data from healthy participants in the coming months

Click image above to view full announcement.


About Lifordi
Lifordi Immunotherapeutics, Inc. is a clinical-stage biotechnology company leading the way by leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and inflammatory disorders. The Company’s lead ADC, LFD-200, is in a Phase 1 clinical trial. Preclinical studies demonstrated efficacy in multiple disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein (VISTA). Lifordi has also applied its novel drug delivery platform to other diverse payloads, such as small molecules, antisense oligonucleotides (ASOs) and siRNA. As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit www.lifordi.com.

About Sanofi Ventures 
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing globally in early-stage biotech and digital health companies aligned with Sanofi’s mission to chase the miracles of science. Areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation.

Contacts:

Theresa McNeely
(508) 523-9511
tmcneely@lifordi.com

Source: Lifordi

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275016

 

View more news from Reportable, Inc.

You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.

If you no longer want to receive messages from us, you can click here to unsubscribe.

Anti-Spam Policy | Privacy Policy

 

The post Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors first appeared on PressReleaseCC.

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors first appeared on Web and IT News.

awnewsor

Recent Posts

How Reliable Wholesale Lamp Parts Supply Supports the Growing Lighting Repair and Restoration Industry

Reliable access to quality lamp parts helps lighting professionals maintain, repair, and restore traditional and…

2 hours ago

New York Medical Center – Inwood Expands Car Accident Care for Upper Manhattan Drivers, Passengers, and Pedestrians

People in Inwood tell us all the time that they thought they were okay after…

2 hours ago

Aquasafe Restoration urges asbestos testing before remodeling Yuma County’s 22,000 pre-1980 homes

Aquasafe Restoration crew members in protective suits and respirators, Yuma, Ariz. Aquasafe Restoration cites census…

2 hours ago

White Pine Web Design Offers Flat Rate Website Pricing for Michigan Small Businesses, Publishes Survey of West Michigan Website Costs

White Pine Web Design publishes every price for Michigan small business websites Every price is…

2 hours ago

Columbus Mother’s Debut Children’s Book Celebrates “Two Kinds of Bright”

Inspired by her boy-girl twins, Two Kinds of Bright invites families to celebrate individuality, neurodiversity,…

2 hours ago

Following Closely in His Footsteps: Equipping Believers for a Deeper Walk with Christ

New York, USA – Nov. 18, 2026 – Following Closely in His Footsteps, by Virginia “Gini”…

2 hours ago

This website uses cookies.